|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | -50.00% |
|
-50.00% | -66.67% |
| 05-28 | Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-30 | Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 671K 476K 418K 389K 358K 45.5M 683K 4.62M 1.81M 22.57M 1.79M 1.75M 77.96M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.17M 1.54M 1.35M 1.26M 1.16M 147M 2.21M 14.94M 5.85M 73.03M 5.79M 5.66M 252M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -50.00% | ||
| 1 week | -50.00% | ||
| 1 month | -50.00% | ||
| 3 months | -66.67% | ||
| 6 months | -66.67% | ||
| Current year | -66.67% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.08 |
| 5 years | 0 | | 0.46 |
| 10 years | 0 | | 4.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 20/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 20/12/2016 |
David Kideckel
CHM | Chairman | - | 27/02/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/10/25 | Other | Chairman | 1,380,000 | 1.2929% | ||
| 03/05/24 | Other | Director | 0 | 0% | ||
| 03/05/24 | Option | Director | 500,000 | 0.5718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -50.00% | -50.00% | -66.67% | -85.71% | 476K | |
| +0.54% | +9.51% | +25.18% | +121.53% | 104B | |
| +0.38% | +5.66% | +48.06% | +154.76% | 54.46B | |
| +2.76% | +3.11% | +3.47% | +279.62% | 23.27B | |
| -0.06% | -1.14% | -13.38% | -20.45% | 8.17B | |
| +0.21% | -6.41% | -34.09% | -36.74% | 7.49B | |
| +2.61% | +4.18% | -8.86% | -27.61% | 6.87B | |
| +0.57% | -1.40% | +18.13% | +25.43% | 6.19B | |
| +0.03% | -1.84% | -0.11% | +25.32% | 5.36B | |
| -1.18% | -0.99% | -6.52% | -9.25% | 3.7B | |
| Average | -4.46% | -0.28% | -3.48% | +42.69% | 21.96B | |
| Weighted average by Cap. | +0.62% | +3.67% | +22.68% | +123.92% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -563K -494K -460K -423K -53.79M -807K -5.46M -2.14M -26.67M -2.11M -2.07M -92.16M | -383K -272K -239K -222K -205K -25.99M -390K -2.64M -1.03M -12.89M -1.02M -999K -44.54M |
| Net Debt | 1.27M 904K 793K 739K 680K 86.38M 1.3M 8.77M 3.43M 42.84M 3.39M 3.32M 148M | 1.5M 1.07M 935K 870K 801K 102M 1.53M 10.33M 4.04M 50.47M 4M 3.91M 174M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- PHRX Stock
Select your edition
All financial news and data tailored to specific country editions
